The company has reported zero revenue for ten consecutive quarters, while operating losses reached $12.1 million in 2026Q1, highlighting a total lack of commercial traction.
| Sales/Revenue | 0 | 800K | 3.5M | 9.16M | 15.62M | 30.98M | 9.19M | 13.75M | 990K |
| Revenue Growth % | - | -77.14% | -61.79% | -41.35% | -49.59% | 237.01% | -33.15% | 1289.19% | - |
| Cost of Goods Sold | 780K | 1.03M | 0 | 1.02M | 64.32M | 47.11M | 44.85M | 24.94M | 38.99M |
| COGS % of Revenue | - | 129.12% | - | 11.14% | 411.84% | 152.03% | 487.79% | 181.33% | 3937.98% |
| Gross Profit | -780K | -233K | 3.5M | 8.14M | -48.7M | -16.12M | -35.65M | -11.19M | -38M |
| Gross Margin % | - | -29.13% | 100% | 88.86% | -311.84% | -52.03% | -387.79% | -81.33% | -3837.98% |
| Gross Profit Growth % | - | -106.66% | -57% | 116.71% | -202.07% | 54.78% | -218.76% | 70.56% | - |
| Operating Expenses | 55.15M | 48.22M | 40.5M | 83.56M | 22.2M | 18.02M | 8.87M | 7.31M | 41.46M |
| OpEx % of Revenue | - | 6027.25% | 1157.14% | 912.19% | 142.15% | 58.14% | 96.43% | 53.13% | 4188.08% |
| Selling, General & Admin | 21.2M | 20.73M | 8.39M | 24.93M | 22.2M | 18.02M | 8.87M | 7.31M | 2.9M |
| SG&A % of Revenue | - | 2590.75% | 239.74% | 272.11% | 142.15% | 58.14% | 96.43% | 53.13% | 292.73% |
| Research & Development | 30.77M | 28.52M | 32.11M | 59.65M | 64.32M | 47.11M | 44.85M | 24.94M | 38.56M |
| R&D % of Revenue | - | 3565.63% | 917.4% | 651.22% | 411.84% | 152.03% | 487.79% | 181.33% | 3895.35% |
| Other Operating Expenses | 1.09M | -1.03M | 0 | -1.02M | -64.32M | -47.11M | -44.85M | -24.94M | 0 |
| Operating Income | -55.93M | -48.45M | -37M | -75.42M | -70.9M | -34.14M | -44.52M | -18.49M | -40.89M |
| Operating Margin % | - | -6056.38% | -1057.14% | -823.33% | -453.99% | -110.18% | -484.22% | -134.46% | -4130.71% |
| Operating Income Growth % | - | -30.95% | 50.94% | -6.36% | -107.7% | 23.32% | -140.75% | 54.78% | - |
| EBITDA | -53.44M | -47.42M | -35.47M | -74.4M | -70.15M | -33.59M | -44.22M | -18.25M | -40.47M |
| EBITDA Margin % | - | -5927.25% | -1013.54% | -812.19% | -449.18% | -108.42% | -480.95% | -132.69% | -4088.08% |
| EBITDA Growth % | -4.41% | -33.67% | 52.32% | -6.05% | -108.83% | 24.03% | -142.31% | 54.91% | - |
| D&A (Non-Cash Add-back) | 648K | 1.03M | 1.53M | 1.02M | 751K | 544K | 300K | 243K | 422K |
| EBIT | -53.78M | -48.45M | -37M | -75.42M | -70.9M | -34.14M | -44.52M | -18.49M | -40.87M |
| Net Interest Income | 5.97M | 2.04M | 7.37M | 7.11M | 2.15M | 23K | 0 | 0 | 0 |
| Interest Income | 6.06M | 2.04M | 7.37M | 7.11M | 2.15M | 23K | 0 | 0 | 0 |
| Interest Expense | 96K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 10.53M | 2.75M | 445K | 7.09M | 2.14M | 23K | 263K | 1.68M | 29K |
| Pretax Income | -45.4M | -45.7M | -36.55M | -68.33M | -68.77M | -34.12M | -44.26M | -16.82M | -40.87M |
| Pretax Margin % | - | -5712.38% | -1044.43% | -745.94% | -440.29% | -110.1% | -481.36% | -122.28% | -4127.78% |
| Income Tax | -325K | -350K | 13K | -162K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.72% | 0.77% | -0.04% | 0.24% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -45.07M | -45.35M | -36.57M | -68.17M | -68.77M | -34.12M | -44.26M | -16.82M | -40.87M |
| Net Margin % | - | -5668.63% | -1044.8% | -744.17% | -440.29% | -110.1% | -481.36% | -122.28% | -4127.78% |
| Net Income Growth % | -8.07% | -24.01% | 46.35% | 0.87% | -101.57% | 22.91% | -163.16% | 58.85% | - |
| Net Income (Continuing) | -45.07M | -45.35M | -36.57M | -68.17M | -68.77M | -34.12M | -44.26M | -16.82M | -40.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.02 | -10.76 | -1.02 | -1.63 | -1.90 | -0.95 | -3.16 | -0.47 | -1.14 |
| EPS Growth % | -439.22% | -954.9% | 37.42% | 14.21% | -100% | 69.94% | -572.34% | 58.77% | - |
| EPS (Basic) | - | -10.76 | -1.02 | -1.63 | -1.90 | -0.95 | -3.16 | -0.47 | -1.14 |
| Diluted Shares Outstanding | 11.21M | 4.87M | 48.26M | 41.74M | 36.19M | 35.98M | 13.99M | 35.85M | 35.85M |
| Basic Shares Outstanding | 11.21M | 4.87M | 48.26M | 41.74M | 36.19M | 35.98M | 13.99M | 35.85M | 35.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Complete Revenue Absence
As indicated by the company's most recent financial filings, ImageneBio has reported zero revenue for every quarter since 2024Q1, marking a total cessation of commercial activity that suggests the firm has transitioned entirely away from any revenue-generating operations or product sales within the current reporting period.
The complete absence of top-line growth over the last eight quarters implies that the company is currently in a pre-commercial or dormant phase. Investors should monitor whether this lack of revenue is a strategic pivot or a sign of fundamental failure in the company's core business model.
Based on the provided income statement data, ImageneBio continues to incur significant quarterly operating expenses, with R&D spending reaching $6.0 million in 2026Q1, despite the total absence of any offsetting revenue streams to support these ongoing capital requirements for the firm's research and development initiatives.
The company's cost structure remains heavily weighted toward R&D, which suggests a continued focus on pipeline development despite the lack of commercial success. The inability to rationalize these costs in the absence of revenue indicates a high burn rate that warrants further investigation by stakeholders.
According to the reported financial statements, ImageneBio's net losses have fluctuated significantly, reaching $10.6 million in 2026Q1, while stock-based compensation remains a recurring expense, totaling $876,000 in the same period, which further complicates the assessment of the company's underlying operational efficiency and true cash burn.
The reliance on stock-based compensation as a significant expense item suggests that the company is attempting to preserve cash by compensating personnel with equity. This practice may indicate potential dilution risks for existing shareholders as the firm continues to operate without a viable path to profitability.
As reported in the historical income statements, the company has sustained negative operating margins for ten consecutive quarters, with the 2026Q1 operating loss of $12.1 million highlighting a structural inability to cover basic operating costs without consistent access to external capital or new revenue sources.
The persistent negative margins suggest that the current business model may be unsustainable without a significant capital injection or a major strategic shift. Investors should be wary of the company's ability to continue operations given the lack of any visible revenue growth or cost-containment success.
Quick answers to the most common questions about buying IMA stock.
For fiscal year 2025, ImageneBio Inc (IMA) reported total revenue of $0.8M. This represents a 19.2% decline compared to $1.0M in 2018.
ImageneBio Inc (IMA) reported a net loss of $45.3M for the fiscal year ending 2025.
ImageneBio Inc (IMA) reported an operating income of $-48.5M, resulting in an operating profit margin of -6056.4%. This margin reflects the operational efficiency of the business before interest and taxes.
ImageneBio Inc (IMA) generated $-0.2M in gross profit for the year, representing a gross profit margin of -29.1%. This demonstrates the company's core pricing power and production efficiency.